At the end of follow-up after all-oral DAA therapy, HIV/HCV-coinfected patients exhibited a significant decrease (q-value <0.05) in liver disease severity markers (LSM, HVPG, bilirubin, aspartate transaminase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), and alkaline phosphatase) and immune-related markers (PD1, PDL1, CXCL10, CXCL8, IL12p70, IL10, and TGFβ) (Table 2). This evidence concerns the gene IL10 and liver disorder.